With full membership, watch our educational and editorial videos, search the site, receive our newsletters, join discussions, download slides and much more.
Dr. Gabriel Steg introduces a discussion between Drs. Anthony Gershlick and Martial Hamon on achieving a balance between favorable outcomes and reducing bleeding in STEMI patients.
Dr. Holmvang presents 2 cases of stent thrombosis to Dr. Kristensen outlining risk factors and potential strategies to prevent this catastrophic event.
What are the implications of recent data on the antiplatelet agents in ACS for Europe? Recorded at the 2009 ACS Masterclass in Copenhagen, Denmark, Dr. Clemmensen leads a roundtable discussion with Drs. Collet, Kristensen, and Schühlen.
Join Drs. Alexander, Becker, and Weitz for a discussion on the coagulation cascade, its link to platelet function, and the risk/benefit and clinical utility of agents that target the coagulation cascade and platelet receptors.
Recently reported and new trials of antiplatelet therapy continue to redefine optimal management strategies for patients with atherothrombotic disease and patients with atrial fibrillation. Drs. Harrington, Angiolillo, Bhatt, Connolly, Mehta, and Simon discuss guidelines? recommendations for the use of antiplatelet therapies and the potential impact of emerging data regarding currently used and novel antiplatelet agents.
With the approval of a third-generation thienopyridine, new clinical trial data on novel agents, and the dosing of clopidogrel, Dr. Berger asks Dr. Cohen how he has incorporated this information into his practice.
After all these years with aspirin and clopidgrel, we are still learning about when and how much of these antiplatelet agents confer the best benefit risk approach. Now new agents like prasugrel add to the options with other new agents on the horizon. Drs Lopes, Granger, Alexander, and Mattos discuss applying trial data to practice in the United States and Latin America.
Carriers of certain CYP genetic variants have lower levels of clopidogrel's active metabolite and experience higher rates of MACE. What role should genotyping play in optimizing antiplatelet therapy? Dr. Simon discusses recent data on these topics with Dr. Mega.
Dual antiplatelet therapy carries a risk for bleeding that is heightened in the setting of oral anticoagulation. What is the best way to manage patients who may need triple therapy? Using a real-world clinical scenario, Dr. Ohman walks through the issues with Drs. Holmes and Moliterno.
Our international panel of experts, Drs. Hamm, Verheugt, Dauerman, and Rao, give their insights into which antiplatelet and antithrombotic agents they prefer to use and when.
Drs. Gurbel, Ohman, and Berger discuss the major issues of optimal duration of dual antiplatelet therapy, balancing the risk/benefit profile, the relevance of point-of-care (POC) monitoring, and consideration to the potential drug-drug interactions between antiplatelet agents and statins/CCBs/PPIs in treating patients with ACS.
PLATO, CURRENT-OASIS 7, and further analyses of PPIs and thienopyridines; read Dr Prasad's review of recent data presented at ESC; and watch presentations by Drs Mehran, O'Donoghue, Storey, and Wiviott.
In the US, each year over 1.4 million people will be hospitalized for unstable angina (UA) and non-ST-segment-elevation myocardial infarction (NSTEMI). Multiple antiplatelet agents have been developed to interfere with or inhibit the specific pathways of platelet activation and aggregation that lead to the development of UA and NSTEMI. Join Drs Newby, Popma, and Wiviot as they discuss.
PLATO, the ESC late-breaking trial, compared a novel direct-acting reversible P2Y12 antagonist with clopidogrel in ACS patients undergoing PCI. Dr. Keith Fox leads a discussion with the PI, Dr. Lars Wallentin, and Dr. Deepak Bhatt.
With the recent approval of a third-generation thienopyridine, choice of agent can be added to the list of considerations in the management of ACS patients, as well as the appropriate timing and dosing of thienopyridine. Using some case vignettes, Dr. King leads a discussion with Drs. Bhatt and Steg on their clinical decision-making.
Patients presenting with STEMI represent a high-risk population. Thrombotic and bleeding complications contribute to mortality in these patients. Join Drs. Steg, Hamm, Hill, and Mehran as they discuss best practices for the treatment of STEMI patients with a focus on preventing bleeding complications.
Antiplatelet therapy is key for the prevention of secondary events in ACS patients. Dr. Ardissino introduces a series of brief presentations by Drs. Angiolillo, Fernánadez-Avilés, Montalescot, and Neumann on the optimal use of antiplatelets in ACS patients undergoing PCI, including those with diabetes and those at high bleeding risk.
How will the prasugrel approval and the upcoming PLATO and CURRENT-OASIS 7 trials affect antiplatelet options for ACS patients undergoing PCI? Read a summary of the latest data, with expert input from Drs. Ardissino and Montalescot.
A patient suffers a STEMI after exploratory laparotomy for suspected gastrinoma; their surgeon insists that no anticoagulation be given. How would you treat? Dr. Rao presents such a complicated case to Dr. Montalescot.
Management of long-term anticoagulation therapy in STEMI patients is challenging. Please join our expert panel, Drs. Elaine Hylek, Ander Cohen, Greg Lip, and Jack Ansell, as they discuss current challenges and strategies to optimize the benefit of and provide insights to the future of anticoagulation therapy.
The treatment options for oral anticoagulation therapy are constantly evolving. Join our expert panel, Drs. Graham Turpie, Jessica L. Mega, Jeffrey Weitz, as they discuss the new data and clinical implications of new anticoagulant medications for patients with ACS
From SOLACI 2009 in Rio de Janeiro. Dr. Mahmud hears how Dr. Feres interprets the data on antiplatelet/antithrombin strategies for his practice in Brazil.
Dr. Holmvang presents 2 cases of stent thrombosis to Dr. Kristensen outlining risk factors and potential strategies to prevent this catastrophic event.
Dr. Gabriel Steg introduces a discussion between Drs. Anthony Gershlick and Martial Hamon on achieving a balance between favorable outcomes and reducing bleeding in STEMI patients.
Our international panel of experts, Drs. Hamm, Verheugt, Dauerman, and Rao, give their insights into which antiplatelet and antithrombotic agents they prefer to use and when.
Join Drs. Alexander, Becker, and Weitz for a discussion on the coagulation cascade, its link to platelet function, and the risk/benefit and clinical utility of agents that target the coagulation cascade and platelet receptors.